# 391: Breaching the IBD efficacy ceiling, and sham surgeries

Page: https://stenobird.com/podcast/the-readout-loud-1134305/391-breaching-the-ibd-efficacy-ceiling-and-sham-surgeries
Text version: https://stenobird.com/podcast/the-readout-loud-1134305/391-breaching-the-ibd-efficacy-ceiling-and-sham-surgeries.md
Podcast: [The Readout Loud](https://stenobird.com/podcast/the-readout-loud-1134305)
Published: 2026-03-05T17:35:00+00:00
Episode link: https://traffic.megaphone.fm/TTSAA9607085727.mp3?updated=1772735911
Audio file: https://traffic.megaphone.fm/TTSAA9607085727.mp3?updated=1772735911
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/391-breaching-the-ibd-efficacy-ceiling-and-sham-surgeries
Duration seconds: 1829

## Resource

Will drugmakers finally be able to breach the efficacy ceiling in inflammatory bowel disease? And is the Food and Drug Administration being flexible enough with rare disease treatments? Spyre Therapeutics CEO Cameron Turtle joins the podcast to discuss his company's experimental IBD medications, and whether the drug industry is scraping the barrel in the search for better treatments. We also discuss the latest news in the life sciences, including the ongoing debate between the FDA and UniQure over its Huntington's disease therapy, as well as Moderna's mammoth patent settlement.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/391-breaching-the-ibd-efficacy-ceiling-and-sham-surgeries/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-readout-loud-1134305/391-breaching-the-ibd-efficacy-ceiling-and-sham-surgeries.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.